美国Covance Research Products(CRP)  www.covance.com www.crpinc.com
CRP，即Covance Research Products，专为生物医学和生物制药学产业提供产品和服务，产品涵盖实验动物、抗体、试剂盒等，尤以神经科学产品见长。
三十年来，位于美国的Covance Research Products公司为生物医学研究提供实验动物和相关服务。CRP还提供抗体产品和相关服务，转基因克隆管理服务并进行临床外科学设备研究。
CRP是第一家建立血统清晰的商业用克隆兔的公司，成功的建立了Caesarean来源的的克隆兔，首先生产杂交兔,并为畸胎学研究人员提供商业化定时交配兔。从只拥有单一的饲养场所发展至今，CRP已经拥有五个养殖点，包括家兔，豚鼠,犬和灵长类动物。自1998年11月与伯克利抗体公司(BabCO)合并后，CRP在抗体供应和服务业务上进展迅速，并扩大了其在创新外科方面的研究能力。

CRP公司提供已经获得ISO9002，AAALAC等认证的仪器设备，为药物开发客户提供高质量、高效率的产品和服务，是CRP一贯的宗旨。
关于CRP的产品和服务
实验动物
犬类：beagles,mongrels,mini-mongrels,hounds
兔类：New Zealand White，Dutch Belted，Watanabe，Californian，Inbred NZW
豚鼠:突变鼠
灵长类动物：Cynomolgus,Rhesus
猪：Domestic Yorkshire
CRP能够利用各种各样的外科手术对其订购的动物进行手术，除此以外，CRP公司还提供行为加强服务，例如对实验动物进行踏车训练或适应实验环境的相关训练。
创新外科和研究服务
CRP提供一系列的创新外科和研究服务，支持药物开发和医学设备研究，除此以外还进行GLP研究。安装动物的动脉导管和医学设备开发在7500平方英尺的外科实验室完成。
抗体产品和服务
CRP提供创新抗体产品和定制抗体服务。客户可以与本公司拥有广泛经验的科学团队合作而受益，公司能帮助客户选择有效抗体产品，提供客户自定义服务。
定制服务包括
多克隆抗体产品 
杂交细胞系的开发
单克隆抗体的开发(体外)
新型抗体产品家族
抗原决定簇抗体
细胞标记物和受体
细胞骨架和细胞表面蛋白
转录因子和信号传导
美国Covance Research Products(CRP)
Covance — one of the world's largest and most comprehensive drug development services companies — has the people, global resources and problem-solving culture to respond to pharmaceutical and biotechnology clients' toughest drug development challenges.
We provide a portfolio of preclinical and clinical development and commercial service offerings — delivered through industry-leading nonclinical testing services, the world's largest central laboratory network, and a global team of clinical trial professionals.
About Covance
Covance Company Overview 

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Offering drug development solutions from preclinical through commercialization, Covance is a world-class provider of the following service lines:
Research products 
Antibody products and services 
Nonclinical development services 
Risk management services 
Clinical pharmacology services 
Central laboratory/Covance local laboratory services 
Cardiac safety services 
Clinical development services 
Commercialization services
Covance — Meeting Your Needs
With a commitment to meeting your needs, Covance offers unparalleled expertise, experience and results. Covance knows the significant pressures pharmaceutical and biotechnology companies of all sizes face in developing and launching drugs backed by strong data.
With a business built around your needs, our streamlined approach to drug development means high quality, error-free data designed to help bring your drug to market as quickly, safely and cost effectively as possible, including:
Proving early safety 
Conducting first in human studies 
Conducting proof of concept studies 
Proving clinical safety and efficacy 
Filing for marketing approval 
Launching and marketing a drug 
Ensuring patient safety and access 
Managing risk
Managing over 15,000 clinical trial protocols in 100 countries on 6 continents, Covance provides the experience and exceptional customer service to advance your compound along the drug development continuum. Strategic partnerships built on decades of success — Covance is dedicated to helping bring your miracles to market sooner. 
In the late 1980s and early 1990s, Corning, Incorporated acquired numerous best-of-class drug development companies, some with roots dating back to the 1940s. In January 1997, Corning spun off these businesses as one publicly-traded, independent company called Covance Inc. [NYSE: CVD].

Covance Today
Today, from its corporate headquarters in Princeton, NJ, Covance has grown into one of the world's largest and most respected global drug development services companies. Moving forward, Covance continues to broaden its capabilities by strategic acquisition and in-house development. The Company's primary focus is serving the pharmaceutical and biotech industries offering a broad range of services — from nonclinical research to clinical development to commercialization services.